| 体内研究: |
Avatrombopag hydrochloride (0.3-3 mg/kg;口服每日一次,连续 14 天) 增加移植人 FL CD34+ 细胞的 NOD/SCID 小鼠的人血小板数量。 |
| 参考文献: |
1. Fukushima-Shintani M, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247-254. 2. Xu H, et al. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Expert Rev Clin Pharmacol. 2019 Sep;12(9):859-865. 3. Nomoto M, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84(5):952-960. |
| 保存条件: |
-80℃,干燥(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.457 ml |
7.287 ml |
14.575 ml |
| 5 mM |
0.291 ml |
1.457 ml |
2.915 ml |
| 10 mM |
0.146 ml |
0.729 ml |
1.457 ml |
| 50 mM |
0.029 ml |
0.146 ml |
0.291 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |